Nemolizumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Nemolizumab: clinical details
Prescribing considerations
- Confirm that the authorised indication, age and weight criteria are met.
- For atopic dermatitis, the licensed indication includes topical corticosteroids and/or topical calcineurin inhibitors.
- Review and, where appropriate, complete age-recommended vaccinations before starting; avoid live vaccines during treatment.
- Evidence is unavailable in patients with uncontrolled asthma because they were excluded from clinical trials.
- Record the product name and batch number for biological-medicine traceability.
- Review clinical response and ongoing treatment suitability.
Contraindications and cautions
- Hypersensitivity to nemolizumab or any listed excipient.
Monitoring
- Monitor for immediate or delayed systemic hypersensitivity and discontinue if it occurs.
- Assess new blistering eruptions for possible bullous pemphigoid.
- Monitor injection-site and eczematous reactions and overall clinical response.
- No routine laboratory-monitoring programme is specified in the product information.
- Report suspected adverse reactions through the Yellow Card Scheme, including brand and batch details where available.
Clinical pharmacology
Nemolizumab is a humanised IgG2 monoclonal antibody that binds selectively to IL-31 receptor alpha and inhibits IL-31 signalling. It is expected to be broken down through normal protein-catabolism pathways rather than significant renal or hepatic elimination.
Formulation and product differences
- The product is a single-use, dual-chamber pre-filled pen containing lyophilised powder and solvent that are mixed within the device before injection.
- Store refrigerated, protected from light and not frozen. Limited room-temperature storage is permitted under the conditions in the product information.
- The prepared solution should be clear and colourless to slightly yellow, without visible particles.
Nemolizumab preparations and strengths
Injection
Route: Parenteral
Strengths: 30 mg
Nemolizumab interactions
No clinically significant effect on medicines processed by the main cytochrome P450 pathways was found in a small study. Vaccination plans still require review.
Live vaccines
Avoid during treatment because their safety and effectiveness with nemolizumab are unknown.
Non-live vaccines
Response data are unavailable, so vaccination status should be reviewed before treatment where possible.
CYP450 substrates, including warfarin, midazolam, omeprazole, metoprolol and caffeine
Clinically significant changes in exposure were not observed, and a pharmacokinetic interaction is not expected.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.